SS-31 peptide (Elamipretide)
SS-31 peptide is an experimental peptide designed to target mitochondrial function, the process by which cells generate energy. The compound has attracted scientific interest because it may help protect mitochondria from oxidative stress and improve cellular energy metabolism.
Elamipretide (also known as SS-31) is being developed by Stealth BioTherapeutics as a potential therapy for diseases associated with mitochondrial dysfunction. As of now, elamipretide remains an investigational compound and has not yet been broadly approved as a medicine.
How SS-31 peptide works
SS-31 belongs to a class of molecules known as mitochondria-targeting peptides. These compounds are designed to accumulate inside mitochondria and interact with components of the inner mitochondrial membrane. Research suggests that SS-31 may:
bind to cardiolipin, a lipid essential for the structure of the inner mitochondrial membrane
help stabilize mitochondrial membranes under conditions of cellular stress
reduce excessive production of reactive oxygen species (ROS)
improve the efficiency of mitochondrial energy production
Because mitochondria are responsible for producing most of the cell’s energy in the form of ATP, improving mitochondrial function could potentially influence a wide range of physiological processes.
For this reason, SS-31 has been studied in several conditions linked to mitochondrial damage or impaired energy metabolism.
Clinical trials and evidence
Elamipretide has been investigated in clinical trials for several diseases associated with mitochondrial dysfunction.
Research programs have explored its potential role in conditions such as:
primary mitochondrial diseases
certain forms of cardiomyopathy
age-related muscle fatigue and mitochondrial decline
rare genetic disorders affecting mitochondrial function
Some studies have reported improvements in measures related to cellular energy metabolism, muscle function, or cardiac performance, although results have varied depending on the disease being studied.
Because mitochondrial disorders are complex and heterogeneous, ongoing research aims to better determine where mitochondria-targeting therapies such as SS-31 may be most beneficial.
Possible side effects of SS-31 peptide:
Clinical trials conducted so far suggest that SS-31 has generally been well tolerated. Reported side effects in studies have included:
mild injection site reactions
headache
fatigue
nausea
Most reported effects have been mild to moderate in severity. However, because the compound is still undergoing clinical investigation, its long-term safety profile has not yet been fully established.